Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine

OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. We performed a retrospective analysis on real-life prospectively collected data in 16 European headache c...

Descripción completa

Detalles Bibliográficos
Autores: Ornello, Raffaele|||0000-0001-9501-4031, Ahmed, Fayyaz|||0000-0002-2746-0889, Negro, Andrea|||0000-0003-3590-298X, Miscio, Anna Maria, Santoro, Antonio|||0000-0002-0798-6816, Alpuente, Alicia|||0000-0001-5296-9401, Russo, Antonio, Silvestro, Marcello, Cevoli, Sabina|||0000-0003-4668-4295, Brunelli, Nicoletta|||0000-0002-8590-9015, Vernieri, Fabrizio|||0000-0002-9594-9336, Grazzi, Licia, Baraldi, Carlo|||0000-0001-8432-1888, Guerzoni, Simona|||0000-0001-9589-2782, Andreou, Anna P.|||0000-0002-7008-6626, Lambru, Giorgio, Frattale, Ilaria|||0000-0001-8733-1299, Kamm, Katharina, Ruscheweyh, Ruth|||0000-0001-9510-7158, Russo, Marco|||0000-0001-5171-8555, Torelli, Paola|||0000-0002-4072-2353, Filatova, Elena, Latysheva, Nina|||0000-0001-9600-5540, Gryglas-Dworak, Anna, Straburzynski, Marcin, Butera, Calogera|||0000-0003-2911-5525, Colombo, Bruno, Filippi, Massimo|||0000-0002-5485-0479, Pozo-Rosich, Patricia|||0000-0003-0796-4702, Martelletti, Paolo|||0000-0002-6556-4128, Sacco, Simona|||0000-0003-0651-1939
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:240760
Acceso en línea:https://ddd.uab.cat/record/240760
https://dx.doi.org/urn:doi:10.1007/s40122-021-00253-0
Access Level:acceso abierto
Palabra clave:Chronic migraine
Multicenter study
OnabotulinumtoxinA
Real-life evidence
id ES_06475a52f82bbcbd4b40bdc12ff6bdd1
oai_identifier_str oai:ddd.uab.cat:240760
network_acronym_str ES
network_name_str España
repository_id_str
spelling Early Management of OnabotulinumtoxinA Treatment in Chronic MigraineInsights from a Real-Life European Multicenter StudyOrnello, Raffaele|||0000-0001-9501-4031Ahmed, Fayyaz|||0000-0002-2746-0889Negro, Andrea|||0000-0003-3590-298XMiscio, Anna MariaSantoro, Antonio|||0000-0002-0798-6816Alpuente, Alicia|||0000-0001-5296-9401Russo, AntonioSilvestro, MarcelloCevoli, Sabina|||0000-0003-4668-4295Brunelli, Nicoletta|||0000-0002-8590-9015Vernieri, Fabrizio|||0000-0002-9594-9336Grazzi, LiciaBaraldi, Carlo|||0000-0001-8432-1888Guerzoni, Simona|||0000-0001-9589-2782Andreou, Anna P.|||0000-0002-7008-6626Lambru, GiorgioFrattale, Ilaria|||0000-0001-8733-1299Kamm, KatharinaRuscheweyh, Ruth|||0000-0001-9510-7158Russo, Marco|||0000-0001-5171-8555Torelli, Paola|||0000-0002-4072-2353Filatova, ElenaLatysheva, Nina|||0000-0001-9600-5540Gryglas-Dworak, AnnaStraburzynski, MarcinButera, Calogera|||0000-0003-2911-5525Colombo, BrunoFilippi, Massimo|||0000-0002-5485-0479Pozo-Rosich, Patricia|||0000-0003-0796-4702Martelletti, Paolo|||0000-0002-6556-4128Sacco, Simona|||0000-0003-0651-1939Chronic migraineMulticenter studyOnabotulinumtoxinAReal-life evidenceOnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers. All the centers provided data on patients treated with BT-A for CM over the first three cycles of treatment. For each treatment cycle we defined patients as "good responders" if reporting a ≥ 50% reduction in monthly headache days compared with the three months before starting BT-A, "partial responders" if reporting a 30-49% reduction in monthly headache days, and "non-responders" if reporting a < 30% reduction in monthly headache days or stopping the treatment before the third cycle. We included 2879 patients. Seven hundred and eighty-four (64.6%) of the 1213 patients reporting a good response during the first and/or the second cycle had a good response during the third cycle; 309 (49.3%) of the 627 patients reporting a partial response (but no good response) during the first and/or the second cycle had a good response during the third cycle; only 65 (6.3%) of the 1039 patients who did not respond during both the first two cycles achieved a good response during the third cycle. Multivariate analyses showed that partial or good response during the first or the second cycle were independently associated with good response during the third cycle. Our data suggest that patients with CM responding to BT-A during the first two cycles will likely benefit from the third cycle of treatment, while the probability that non-responders to the first two cycles start responding during the third cycle is low. These results can help guide the individual decision to stop or continue treatment after the second cycle in patients who have not responded to the first two cycles. The online version contains supplementary material available at 10.1007/s40122-021-00253-0.Universitat Autònoma de Barcelona 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/240760https://dx.doi.org/urn:doi:10.1007/s40122-021-00253-0reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2407602026-06-06T12:50:31Z
dc.title.none.fl_str_mv Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
Insights from a Real-Life European Multicenter Study
title Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
spellingShingle Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
Ornello, Raffaele|||0000-0001-9501-4031
Chronic migraine
Multicenter study
OnabotulinumtoxinA
Real-life evidence
title_short Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
title_full Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
title_fullStr Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
title_full_unstemmed Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
title_sort Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine
dc.creator.none.fl_str_mv Ornello, Raffaele|||0000-0001-9501-4031
Ahmed, Fayyaz|||0000-0002-2746-0889
Negro, Andrea|||0000-0003-3590-298X
Miscio, Anna Maria
Santoro, Antonio|||0000-0002-0798-6816
Alpuente, Alicia|||0000-0001-5296-9401
Russo, Antonio
Silvestro, Marcello
Cevoli, Sabina|||0000-0003-4668-4295
Brunelli, Nicoletta|||0000-0002-8590-9015
Vernieri, Fabrizio|||0000-0002-9594-9336
Grazzi, Licia
Baraldi, Carlo|||0000-0001-8432-1888
Guerzoni, Simona|||0000-0001-9589-2782
Andreou, Anna P.|||0000-0002-7008-6626
Lambru, Giorgio
Frattale, Ilaria|||0000-0001-8733-1299
Kamm, Katharina
Ruscheweyh, Ruth|||0000-0001-9510-7158
Russo, Marco|||0000-0001-5171-8555
Torelli, Paola|||0000-0002-4072-2353
Filatova, Elena
Latysheva, Nina|||0000-0001-9600-5540
Gryglas-Dworak, Anna
Straburzynski, Marcin
Butera, Calogera|||0000-0003-2911-5525
Colombo, Bruno
Filippi, Massimo|||0000-0002-5485-0479
Pozo-Rosich, Patricia|||0000-0003-0796-4702
Martelletti, Paolo|||0000-0002-6556-4128
Sacco, Simona|||0000-0003-0651-1939
author Ornello, Raffaele|||0000-0001-9501-4031
author_facet Ornello, Raffaele|||0000-0001-9501-4031
Ahmed, Fayyaz|||0000-0002-2746-0889
Negro, Andrea|||0000-0003-3590-298X
Miscio, Anna Maria
Santoro, Antonio|||0000-0002-0798-6816
Alpuente, Alicia|||0000-0001-5296-9401
Russo, Antonio
Silvestro, Marcello
Cevoli, Sabina|||0000-0003-4668-4295
Brunelli, Nicoletta|||0000-0002-8590-9015
Vernieri, Fabrizio|||0000-0002-9594-9336
Grazzi, Licia
Baraldi, Carlo|||0000-0001-8432-1888
Guerzoni, Simona|||0000-0001-9589-2782
Andreou, Anna P.|||0000-0002-7008-6626
Lambru, Giorgio
Frattale, Ilaria|||0000-0001-8733-1299
Kamm, Katharina
Ruscheweyh, Ruth|||0000-0001-9510-7158
Russo, Marco|||0000-0001-5171-8555
Torelli, Paola|||0000-0002-4072-2353
Filatova, Elena
Latysheva, Nina|||0000-0001-9600-5540
Gryglas-Dworak, Anna
Straburzynski, Marcin
Butera, Calogera|||0000-0003-2911-5525
Colombo, Bruno
Filippi, Massimo|||0000-0002-5485-0479
Pozo-Rosich, Patricia|||0000-0003-0796-4702
Martelletti, Paolo|||0000-0002-6556-4128
Sacco, Simona|||0000-0003-0651-1939
author_role author
author2 Ahmed, Fayyaz|||0000-0002-2746-0889
Negro, Andrea|||0000-0003-3590-298X
Miscio, Anna Maria
Santoro, Antonio|||0000-0002-0798-6816
Alpuente, Alicia|||0000-0001-5296-9401
Russo, Antonio
Silvestro, Marcello
Cevoli, Sabina|||0000-0003-4668-4295
Brunelli, Nicoletta|||0000-0002-8590-9015
Vernieri, Fabrizio|||0000-0002-9594-9336
Grazzi, Licia
Baraldi, Carlo|||0000-0001-8432-1888
Guerzoni, Simona|||0000-0001-9589-2782
Andreou, Anna P.|||0000-0002-7008-6626
Lambru, Giorgio
Frattale, Ilaria|||0000-0001-8733-1299
Kamm, Katharina
Ruscheweyh, Ruth|||0000-0001-9510-7158
Russo, Marco|||0000-0001-5171-8555
Torelli, Paola|||0000-0002-4072-2353
Filatova, Elena
Latysheva, Nina|||0000-0001-9600-5540
Gryglas-Dworak, Anna
Straburzynski, Marcin
Butera, Calogera|||0000-0003-2911-5525
Colombo, Bruno
Filippi, Massimo|||0000-0002-5485-0479
Pozo-Rosich, Patricia|||0000-0003-0796-4702
Martelletti, Paolo|||0000-0002-6556-4128
Sacco, Simona|||0000-0003-0651-1939
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Chronic migraine
Multicenter study
OnabotulinumtoxinA
Real-life evidence
topic Chronic migraine
Multicenter study
OnabotulinumtoxinA
Real-life evidence
description OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response. We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers. All the centers provided data on patients treated with BT-A for CM over the first three cycles of treatment. For each treatment cycle we defined patients as "good responders" if reporting a ≥ 50% reduction in monthly headache days compared with the three months before starting BT-A, "partial responders" if reporting a 30-49% reduction in monthly headache days, and "non-responders" if reporting a < 30% reduction in monthly headache days or stopping the treatment before the third cycle. We included 2879 patients. Seven hundred and eighty-four (64.6%) of the 1213 patients reporting a good response during the first and/or the second cycle had a good response during the third cycle; 309 (49.3%) of the 627 patients reporting a partial response (but no good response) during the first and/or the second cycle had a good response during the third cycle; only 65 (6.3%) of the 1039 patients who did not respond during both the first two cycles achieved a good response during the third cycle. Multivariate analyses showed that partial or good response during the first or the second cycle were independently associated with good response during the third cycle. Our data suggest that patients with CM responding to BT-A during the first two cycles will likely benefit from the third cycle of treatment, while the probability that non-responders to the first two cycles start responding during the third cycle is low. These results can help guide the individual decision to stop or continue treatment after the second cycle in patients who have not responded to the first two cycles. The online version contains supplementary material available at 10.1007/s40122-021-00253-0.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/240760
https://dx.doi.org/urn:doi:10.1007/s40122-021-00253-0
url https://ddd.uab.cat/record/240760
https://dx.doi.org/urn:doi:10.1007/s40122-021-00253-0
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402908283371520
score 15,301603